Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men
This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.
The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.
LambdaGuide measurements will not be used to guide or modify clinical care.
Обзор исследования
Статус
Статус
Условия
Условия
Подробное описание
This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.
The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.
Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.
During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.
For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.
Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.
Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.
The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Sarah Lapp
- Номер телефона: 678-231-0685
- Электронная почта: sarah@lambdasurgical.com
Места учебы
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Рекрутинг
- PINE (Prostate Institution of New England)
-
Контакт:
- Alethia Chan
- Номер телефона: 857-800-2305
- Электронная почта: chanalethia@gmail.com
-
Главный следователь:
- Louis Liou, MD, PhD
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.
Описание
Inclusion Criteria:
- Adult male subject (22 years of age or older).
- Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
- Able and willing to provide informed consent before study participation.
- Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
- Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
- Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.
Exclusion Criteria:
- Participation is expected to interfere with or materially delay standard clinical care.
- Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
- Inability to provide informed consent.
- Inability to use the required compatible cystoscope or approved study configuration.
- Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: CASE_ONLY
- Временные перспективы: PROSPECTIVE
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Clinical measurement feasibility
Временное ограничение: Procedure duration
|
Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained. |
Procedure duration
|
|
Primary safety endpoint
Временное ограничение: From procedure date to 30 days after (+/-5 days)
|
Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events. |
From procedure date to 30 days after (+/-5 days)
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Calibration success
Временное ограничение: During Procedure
|
Calibration success |
During Procedure
|
|
Camera deployment and expected image display
Временное ограничение: During Procedure
|
Camera deployment and expected image display |
During Procedure
|
|
Spatial capture success
Временное ограничение: During Procedure
|
Spatial capture success |
During Procedure
|
|
Valid point-selection success
Временное ограничение: During Procedure
|
Valid point-selection success |
During Procedure
|
|
Successful measurement completion
Временное ограничение: During Procedure
|
Successful measurement completion |
During Procedure
|
|
Calibration and measurement time
Временное ограничение: During Procedure
|
Calibration and measurement time (descriptive only) |
During Procedure
|
|
Procedure interference
Временное ограничение: During Procedure
|
Procedure interference |
During Procedure
|
|
User acceptance
Временное ограничение: During Procedure
|
User acceptance - based on Investigator Questionnaire |
During Procedure
|
|
Observational comparative measurements (
Временное ограничение: During Procedure
|
Observational comparative measurements (descriptive only) |
During Procedure
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Главный следователь: Louis Liou, MD, PhD, PINE - Prostate Institution of New England
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- LG-GU-001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .